Literature DB >> 19858078

Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia.

Yaroslau Compta1, Joan Santamaria, Luca Ratti, Eduardo Tolosa, Alex Iranzo, Esteban Muñoz, Francesc Valldeoriola, Roser Casamitjana, Jose Ríos, Maria J Marti.   

Abstract

Excessive daytime sleepiness is common in Parkinson's disease and has been associated with Parkinson's disease-related dementia. Narcoleptic features have been observed in Parkinson's disease patients with excessive daytime sleepiness and hypocretin cell loss has been found in the hypothalamus of Parkinson's disease patients, in association with advanced disease. However, studies on cerebrospinal fluid levels of hypocretin-1 (orexin A) in Parkinson's disease have been inconclusive. Reports of sleep studies in Parkinson's disease patients with and without excessive daytime sleepiness have also been disparate, pointing towards a variety of causes underlying excessive daytime sleepiness. In this study, we aimed to measure cerebrospinal fluid hypocretin-1 levels in Parkinson's disease patients with and without dementia and to study their relationship to dementia and clinical excessive daytime sleepiness, as well as to describe potentially related sleep architecture changes. Twenty-one Parkinson's disease patients without dementia and 20 Parkinson's disease patients with dementia, along with 22 control subjects without sleep complaints, were included. Both Epworth sleepiness scale, obtained with the help of the caregivers, and mini-mental state examination were recorded. Lumbar cerebrospinal fluid hypocretin-1 levels were measured in all individuals using a radio-immunoassay technique. Additionally, eight Parkinson's disease patients without dementia and seven Parkinson's disease patients with dementia underwent video-polysomnogram and multiple sleep latencies test. Epworth sleepiness scale scores were higher in Parkinson's disease patients without dementia and Parkinson's disease patients with dementia than controls (P < 0.01) and scores >10 were more frequent in Parkinson's disease patients with dementia than in Parkinson's disease patients without dementia (P = 0.04). Cerebrospinal fluid hypocretin-1 levels were similar among groups (controls = 321.15 +/- 47.15 pg/ml; without dementia = 300.99 +/- 58.68 pg/ml; with dementia = 309.94 +/- 65.95 pg/ml; P = 0.67), and unrelated to either epworth sleepiness scale or mini-mental state examination. Dominant occipital frequency awake was slower in Parkinson's disease patients with dementia than Parkinson's disease patients without dementia (P = 0.05). Presence of slow dominant occipital frequency and/or loss of normal non-rapid eye movement sleep architecture was more frequent among Parkinson's disease patients with dementia (P = 0.029). Thus, excessive daytime sleepiness is more frequent in Parkinson's disease patients with dementia than Parkinson's disease patients without dementia, but lumbar cerebrospinal fluid hypocretin-1 levels are normal and unrelated to severity of sleepiness or the cognitive status. Lumbar cerebrospinal fluid does not accurately reflect the hypocretin cell loss known to occur in the hypothalamus of advanced Parkinson's disease. Alternatively, mechanisms other than hypocretin cells dysfunction may be responsible for excessive daytime sleepiness and the sleep architecture alterations seen in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858078     DOI: 10.1093/brain/awp263

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  29 in total

1.  Reduced hypocretin (orexin) levels in dementia with Lewy bodies.

Authors:  Stephanie Lessig; Kiren Ubhi; Douglas Galasko; Anthony Adame; Emiley Pham; Kelly Remidios; Michael Chang; Lawrence A Hansen; Eliezer Masliah
Journal:  Neuroreport       Date:  2010-08-04       Impact factor: 1.837

2.  Scoring sleep in neurological patients: the need for specific considerations.

Authors:  Joan Santamaria; Birgit Högl; Claudia Trenkwalder; Donald Bliwise
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

3.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

4.  Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic.

Authors:  S Gulyani; R Salas; Z Mari; S Choi; A Mahajan; C Gamaldo
Journal:  Basal Ganglia       Date:  2016-05-27

5.  Sleep Disorders in Atypical Parkinsonism.

Authors:  Sabra M Abbott; Aleksandar Videnovic
Journal:  Mov Disord Clin Pract       Date:  2014-06-01

6.  Reduced Rapid Eye Movement Density in Parkinson Disease: A Polysomnography-Based Case-Control Study.

Authors:  Lynn A Schroeder; Olivier Rufra; Nicolas Sauvageot; François Fays; Vannina Pieri; Nico J Diederich
Journal:  Sleep       Date:  2016-12-01       Impact factor: 5.849

Review 7.  Parkinson's disease and sleep/wake disturbances.

Authors:  Keisuke Suzuki; Masayuki Miyamoto; Tomoyuki Miyamoto; Koichi Hirata
Journal:  Curr Neurol Neurosci Rep       Date:  2015-03       Impact factor: 5.081

8.  Widespread cortical and subcortical brain atrophy in Parkinson's disease with excessive daytime sleepiness.

Authors:  S Kato; H Watanabe; J Senda; M Hirayama; M Ito; N Atsuta; T Kaga; M Katsuno; S Naganawa; G Sobue
Journal:  J Neurol       Date:  2011-08-18       Impact factor: 4.849

Review 9.  Olfactory Dysfunction in Neurodegenerative Diseases.

Authors:  Concepció Marin; Dolores Vilas; Cristóbal Langdon; Isam Alobid; Mauricio López-Chacón; Antje Haehner; Thomas Hummel; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-15       Impact factor: 4.806

Review 10.  RBD and Neurodegenerative Diseases.

Authors:  Haiyang Jiang; Jinsha Huang; Yan Shen; Shiyi Guo; Luxi Wang; Chao Han; Ling Liu; Kai Ma; Yun Xia; Jie Li; Xiaoyun Xu; Nian Xiong; Tao Wang
Journal:  Mol Neurobiol       Date:  2016-03-31       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.